The European Agency for the Evaluation of Medicinal Products
Evaluation of Medicines for Human Use

London, 22 May 2001
Doc. Ref: EMEA/37043/00

WITHDRAWAL OF THE MARKETING AUTHORISATION FOR THE MEDICINAL PRODUCT "EchoGen - dodecafluoropentane" EU/1/98/072/001

- On 17 July 1998, the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product EchoGen, which contains dodecafluoropentane. The pharmaceutical company responsible for this medicinal product is Sonus Pharmaceuticals Ltd.
- On 8 November 2000, the Marketing Authorisation holder notified the European Commission of its decision to withdraw the Marketing Authorisation for EchoGen.
- On 22 January 2001, the European Commission adopted the decision withdrawing the Marketing Authorisation for the medicinal product for human use "EchoGen - dodecafluoropentane". Pursuant to this decision the European Public Assessment Report for EchoGen has been removed from the EMEA website.
- For information, it should be noted that the product had never been marketed within the European Economic Area.

Noel Wathion
Head of Unit for the Post-Authorisation Evaluation
of Medicinal Products for Human Use

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK
Tel (44-20-7) 418 8400 Fax (44-20-7) 418 8613
E-mail: mail@emea.eudra.org http://www.emea.eu.int